Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;17(4):713-38, vii.
doi: 10.1016/j.chc.2008.06.009.

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders

Affiliations
Review

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders

Michael G Aman et al. Child Adolesc Psychiatr Clin N Am. 2008 Oct.

Abstract

We reviewed the recent literature on medicines used to manage inattention, impulsiveness, and overactivity in children with pervasive developmental disorders (autistic disorder, pervasive developmental disorder not otherwise specified, Asperger's disorder) using computer searches of pharmacologic studies. A substantial number of reports were identified and summarized. The literature tends to be dominated by uncontrolled studies, although the number of controlled trials is growing. Findings are described for psychostimulants, noradrenergic reuptake inhibitors, antipsychotics, alpha adrenergic agonists, antidepressants, anxiolytics, cholinesterase inhibitors, N-methyl-D-aspartate receptor blockers, and antiepileptic mood stabilizers. Evidence for a positive effect is strongest for psychostimulants, noradrenergic reuptake inhibitors, antipsychotics, and alpha adrenergic agonists. Evidence for efficacy seems weakest for newer antidepressants, anxiolytics, and mood stabilizers.

PubMed Disclaimer

References

    1. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006;36:1101–14. - PubMed
    1. Aman MG, Tassé MJ, Rojahn J, et al. The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17:41–57. - PubMed
    1. Arnold LE, Gadow KD, Pearson DA, et al. Stimulants. In: Reiss S, Aman MG, editors. Psychotropic medication and developmental disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University Nisonger Center; 1998. pp. 229–57.
    1. Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with low IQ and ADHD: Analysis of three aggregated studies. J Child Adolesc Psychopharmacol. 2003;13:27–38. - PubMed
    1. Pearson D, Lane D, Santos C, et al. Effects of methylphenidate treatment in children with mental retardation and ADHD: Individual variation in medication response. J Am Acad Child Adolesc Psychiatry. 2004;43:686–98. - PubMed

Publication types

MeSH terms

Substances